This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -226.47% and 60.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 62.86% and 15.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Here's Why Investors Should Invest in Arcturus Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
New Strong Buy Stocks for September 13th
by Zacks Equity Research
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
by Zacks Equity Research
BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
by Zacks Equity Research
Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
by Zacks Equity Research
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
AstraZeneca (AZN) Denies Rumors About UK Facility Relocation
by Zacks Equity Research
Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
by Zacks Equity Research
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
Here's Why You Should Consider Buying Akebia (AKBA) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
by Zacks Equity Research
The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
by Zacks Equity Research
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
by Zacks Equity Research
Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.
New Strong Buy Stocks for August 23rd
by Zacks Equity Research
RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
by Zacks Equity Research
A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).